Yanlin Pu
Chongqing Key Laboratory For The Prevention And Treatment Of Major Blinding Eye Diseases, Chongqing Branch Of National Clinical Research Centre For Ocular Diseases
Chongqing, China
Chongqing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
DNA 5-Hydroxymethylcytosine Landscape and Transcriptional Profile Highlight the TUBB4B-Mediated Th17/Th1/Treg Imbalance in Behçet's Uveitis.
Journal: Investigative ophthalmology & visual science
Published: August 12, 2025
Ocular Hypertension or Glaucoma Risk Factor Prediction Models for Patients with Fuchs Uveitis Syndrome.
Journal: Ocular immunology and inflammation
Published: June 11, 2025
Cardiac oxidative damage and mitochondrial dysfunction induced by manganese deficiency are probably associated with the inhibition of the Nrf2 signaling pathway.
Journal: Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine
Published: April 15, 2025
The Right to Women's Sight: Global, Regional, and National Burden of Blindness and Vision Loss in Women, 1990 to 2021.
Journal: American journal of ophthalmology
Published: February 13, 2025
Integrated analysis of genetic, proteinic, and metabolomic alterations in Behcet's disease.
Journal: Scientific reports
Published: October 21, 2024
Corneal Endothelial Changes in Chinese Patients with Fuchs' Uveitis Syndrome.
Journal: Ocular immunology and inflammation
Published: October 21, 2024
TET2-mediated upregulation of 5-hydroxymethylcytosine in LRRC39 promoter promotes Th1 response in association with downregulated Treg response in Vogt-Koyanagi-Harada disease.
Journal: Clinical immunology (Orlando, Fla.)
Published: March 06, 2023
Vogt-Koyanagi-Harada disease in pediatric, adult and elderly: clinical characteristics and visual outcomes.
Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
Published: December 06, 2022
A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease.
Journal: Nature communications
Published: October 27, 2022
Showing 1-10 of 10
Last Updated: 09/26/2026